Quantitative assessment of lung cancer perfusion using MDCT: Does measurement reproducibility improve with greater tumor volume coverage?

American Journal of Roentgenology

Volumn 187, Issue 4, 2006, Pages 1079-1084

  Ng, Quan Sing ^a   Goh, Vicky ^a   Klotz, Ernst ^b   Fichte, Heinz ^b   Saunders, Michele I ^a   Hoskin, Peter J ^a   Padhani, Anwar R ^a  

^a MOUNT VERNON HOSPITAL   (United Kingdom)

^b SIEMENS AG   (Germany)

Author keywords

Lung; Lung diseases; MDCT; Neoplasms; Oncologic imaging; Perfusion CT

Indexed keywords

IOBITRIDOL; XENETIX 300;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; FEMALE; HUMAN; LUNG CANCER; LUNG NON SMALL CELL CANCER; MALE; MODIFIED DISCRETE COSINE TRANSFORM; PRIORITY JOURNAL; REPRODUCIBILITY; STATISTICAL ANALYSIS; TUMOR VASCULARIZATION; TUMOR VOLUME;

AGED; BLOOD VOLUME; CARCINOMA, NON-SMALL-CELL LUNG; FEMALE; HUMANS; IMAGE PROCESSING, COMPUTER-ASSISTED; LUNG NEOPLASMS; MALE; MIDDLE AGED; REPRODUCIBILITY OF RESULTS; TOMOGRAPHY, X-RAY COMPUTED; TUMOR BURDEN;

EID: 33748992003     PISSN: 0361803X     EISSN: None     Source Type: Journal    
DOI: 10.2214/AJR.05.0889     Document Type: Article

References (30)

1. Tozer GM. Measuring tumor vascular response to antivascular and antiangiogenic drugs. Br J Radiol 2003; 76:S23-S35
2. World Health Organization. WHO handbook for reporting results of cancer treatment. Geneva, Switzerland: World Health Organization, 1979: WHO offset publication no. 48
3. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 2000; 92:205-216
4. Kerbel R, Folkman J. Clinical translation of angiogenesis inhibitors. Nat Rev Cancer 2000; 2:727-739
5. Willett CG, Boucher Y, Di Tomaso E, et al. Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer. Nat Med 2004; 10:145-147
6. Anderson HL, Yap JT, Miller MP, Robbins A, Jones T, Price PM. Assessment of pharmacodynamic vascular response in a phase I trial of combretastatin A4 phosphate. J Clin Oncol 2003; 21:2823-2830
7. Galbraith SM, Maxwell RJ, Lodge MA, et al. Combretastatin A4 phosphate has tumor antivascular activity in rat and man as demonstrated by dynamic magnetic resonance imaging. J Clin Oncol 2003; 21:2831-2842
8. Stevenson JP, Rosen M, Sun W, et al. Phase I trial of the antivascular agent combretastatin A4 phosphate on a 5-day schedule to patients with cancer: magnetic resonance imaging evidence for altered tumor blood flow. J Clin Oncol 2003; 21:4428-4438
9. Purdie TG, Henderson E, Lee TY. Functional CT imaging of angiogenesis in rabbit VX2 soft-tissue tumor. Phys Med Biol 2001; 46:3161-3175
10. Cenic A, Nabavi DG, Craen RA, Gelb AW, Lee TY. Dynamic CT measurement of cerebral blood flow: a validation study. AJNR 1999; 20:63-73
11. Gobbel GT, Cann CE, Iwamoto HS, Fike JR. Measurement of regional cerebral blood flow in the dog using ultrafasl computed tomography: experimental validation. Stroke 1991; 22:772-779
12. Gobbel GT, Cann CE, Fike JR. Comparison of xenon-enhanced CT with ultrafasl CT for measurement of regional cerebral blood flow. AJNR 1993; 14:543-550
13. Wintermark M, Thiran JP, Maeder P, Schnyder P, Meuli R. Simultaneous measurement of regional cerebral blood flow by perfusion CT and stable xenon CT: a validation study. AJNR 2001; 22:905-914
14. 2(15)O positron emission tomography. Neurol Res 2000; 22:457-464
15. Jinzaki M, Tanimoto A, Mukai M, et al. Double phase helical CT of small renal parenchymal neoplasms: correlation with pathologic findings and tumor angiogenesis. J Comput Assist Tomogr 2000; 24:835-842
16. Yi CA, Lee KS, Kim EA, et al. Solitary pulmonary nodules: dynamic enhanced multidetector row CT study and comparison with vascular endothelial growth factor and microvessel density. Radiology 2004; 233:191-199
17. Tateishi U, Nishihara H, Tsukamoto E, Morikawa T, Tamaki N, Miyasaka K. Lung tumors evaluated with FDG-PET and dynamic CT: the relationship between vascular density and glucose metabolism. J Comput Assist Tomogr 2002; 26:185-190
18. Chaplin DJ, Hill SA. Temporal heterogeneity in microregional erythrocyte flux in experimental solid tumors. Br J Cancer 1995; 71:1210-1213
19. Kimura H, Braun RD, Ong ET, et al. Fluctuations in red cell flux in tumor microvessels can lead to transient hypoxia and reoxygenation in tumor parenchyma. Cancer Res 1996; 56:5522-5528
20. Patlak CS, Balsberg RG, Femstmacher JD. Graphical evaluation of blood to brain transfer constants from multiple time uptake data. J Cereb Blood Flow Metab 1983; 3:1-7
21. Bland JM, Altman DG. Statistical methods for assessing agreement between two methods of clinical measurement. Lancet 1986; 1:307-310
22. Bland JM, Altman DG. Statistics notes: measurement error. BMJ 1996; 312:1654,
23. corrected and republished in BMJ 1996; 313:1654
24. Bland JM, Altman DG. Statistics notes: measurement error proportional to the mean. BMJ 1996; 313:106
25. Bland JM, Altman DG. Measuring agreement in method comparison studies. Stat Methods Med Res 1999; 8:135-160
26. Bland JM, Altman DG. Applying the right statistics: analysis of measurement studies. Ultrasound Obstet Gynecol 2003; 22:85-93
27. Miles KA, Griffiths MR, Fuentes MA. Standardized perfusion value: universal CT contrast enhancement scale that correlates with FDG-PET in lung nodules. Radiology 2001; 220:548-553
28. Nabavi DG, Cenic A, Dool J, et al. Quantitative assessment of cerebral hemodynamics using CT: stability, accuracy, and precision studies in dogs. J Comput Assist Tomogr 1999; 23:506-515
29. Cenic A, Nabavi DG, Craen RA, Gelb AW, Lee TY. A CT method to measure hemodynamics in brain tumors: validation and application of cerebral blood flow maps. AJNR 2000; 21:462-470
30. Galbraith SM, Lodge MA, Taylor NJ, et al. Reproducibility of dynamic contrast-enhanced MRI in human muscle and tumors: comparison of quantitative and semi-quantitative analysis. NMR Biomed 2002; 15:132-142